Health Catalyst - HCAT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.71
  • Forecasted Upside: 53.05%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$7.65
▼ -0.8 (-9.47%)

This chart shows the closing price for HCAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Health Catalyst Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAT

Analyst Price Target is $11.71
▲ +53.05% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $11.71, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a 53.05% upside from the last price of $7.65.

This chart shows the closing price for HCAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Health Catalyst. This rating has held steady since July 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/19/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/18/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024StephensBoost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.00
11/13/2024CitigroupBoost TargetBuy ➝ Buy$9.00 ➝ $10.50
11/7/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$8.00 ➝ $9.00
10/8/2024Evercore ISIBoost TargetOutperform ➝ Outperform$8.00 ➝ $10.00
10/4/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
9/4/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$10.00 ➝ $13.00
8/26/2024Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $11.00
8/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
8/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
8/8/2024StephensLower TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
7/9/2024Evercore ISILower TargetOutperform ➝ Outperform$9.00 ➝ $8.00
6/6/2024Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $14.00
5/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/10/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$14.00 ➝ $13.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00
4/10/2024KeyCorpReiterated RatingOverweight ➝ Sector Weight
3/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00
2/26/2024KeyCorpLower TargetOverweight ➝ Overweight$12.00 ➝ $10.00
2/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$17.00 ➝ $15.00
2/23/2024Evercore ISILower TargetOutperform ➝ Outperform$11.00 ➝ $10.00
2/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$12.00 ➝ $11.00
1/26/2024GuggenheimUpgradeNeutral ➝ Buy$14.00
1/3/2024BarclaysInitiated CoverageOverweight$14.00
1/3/2024Evercore ISIUpgradeIn-Line ➝ Outperform$9.00 ➝ $11.00
12/22/2023Piper SandlerBoost TargetOverweight ➝ Overweight$11.00 ➝ $12.00
12/13/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$14.00 ➝ $11.00
11/13/2023Piper SandlerUpgradeNeutral ➝ Overweight$12.00 ➝ $11.00
11/1/2023Stifel NicolausLower TargetHold ➝ Hold$15.00 ➝ $12.00
10/30/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$13.00 ➝ $8.00
10/11/2023Evercore ISILower Target$14.00 ➝ $10.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00
8/29/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $14.00
8/1/2023Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$16.00
5/10/2023Raymond JamesDowngradeOutperform ➝ Market Perform
5/10/2023GuggenheimDowngradeBuy ➝ Neutral
4/11/2023StephensInitiated CoverageEqual Weight$13.00
4/4/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$13.00 ➝ $16.00
3/24/2023CitigroupLower TargetBuy$17.00 ➝ $16.00
3/8/2023CitigroupBoost TargetBuy$16.00 ➝ $17.00
3/6/2023Wells Fargo & CompanyBoost TargetEqual Weight$11.00 ➝ $13.00
3/2/2023Raymond JamesBoost TargetStrong-Buy$15.00 ➝ $18.00
3/1/2023Royal Bank of CanadaBoost TargetSector Perform$9.00 ➝ $15.00
11/15/2022Evercore ISILower Target$10.00
11/15/2022BTIG ResearchLower Target$17.00
11/10/2022Raymond JamesLower TargetStrong-Buy$20.00 ➝ $15.00
11/9/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$19.00 ➝ $15.00
11/9/2022Piper SandlerLower Target$11.00 ➝ $8.00
11/9/2022Leerink PartnersLower TargetOutperform$20.00 ➝ $17.00
10/31/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$10.00
10/25/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$19.00 ➝ $9.00
9/26/2022BTIG ResearchLower TargetBuy$25.00 ➝ $21.00
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
9/13/2022Piper SandlerDowngradeOverweight ➝ Neutral$21.00 ➝ $11.00
8/10/2022The Goldman Sachs GroupLower TargetBuy$29.00 ➝ $18.00
8/5/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $16.00
8/5/2022Stifel NicolausDowngradeBuy ➝ Hold$27.00 ➝ $16.00
7/27/2022BTIG ResearchLower Target$35.00 ➝ $25.00
5/26/2022The Goldman Sachs GroupLower TargetBuy$42.00 ➝ $37.00
5/11/2022Canaccord Genuity GroupLower Target$35.00 ➝ $17.00
5/11/2022Royal Bank of CanadaLower Target$35.00 ➝ $19.00
5/11/2022CitigroupLower Target$45.00 ➝ $25.00
5/11/2022Piper SandlerLower Target$38.00 ➝ $21.00
4/13/2022GuggenheimInitiated CoverageBuy$39.00
3/25/2022BTIG ResearchLower TargetBuy$60.00 ➝ $50.00
3/17/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00 ➝ $28.00
3/7/2022Piper SandlerLower TargetOverweight$66.00 ➝ $38.00
3/4/2022Raymond JamesLower TargetStrong-Buy$70.00 ➝ $40.00
3/2/2022Canaccord Genuity GroupLower Target$62.00 ➝ $35.00
3/2/2022Royal Bank of CanadaLower TargetOutperform$66.00 ➝ $35.00
3/2/2022Leerink PartnersLower TargetOutperform$64.00 ➝ $48.00
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$48.00
12/20/2021CitigroupLower TargetBuy$68.00 ➝ $55.00
12/1/2021Jefferies Financial GroupInitiated CoverageHold$48.00
10/14/2021BTIG ResearchInitiated CoverageBuy$60.00
9/26/2021Leerink PartnersReiterated RatingBuy
8/10/2021Raymond JamesBoost TargetStrong-Buy$66.00 ➝ $70.00
8/10/2021Royal Bank of CanadaBoost TargetOutperform$60.00 ➝ $66.00
8/9/2021CitigroupBoost TargetBuy$62.00 ➝ $68.00
8/6/2021Leerink PartnersBoost TargetOutperform$62.00 ➝ $64.00
8/6/2021Piper SandlerBoost TargetOverweight$57.00 ➝ $66.00
6/30/2021Leerink PartnersBoost TargetOutperform$59.00 ➝ $62.00
6/28/2021Raymond JamesReiterated RatingBuy$66.00
5/7/2021The Goldman Sachs GroupBoost TargetBuy$54.00 ➝ $60.00
5/7/2021Raymond JamesBoost TargetStrong-Buy$56.00 ➝ $63.00
5/7/2021Leerink PartnersBoost TargetOutperform$53.00 ➝ $59.00
5/7/2021Cantor FitzgeraldBoost TargetOverweight$52.00 ➝ $60.00
5/7/2021Piper SandlerBoost TargetOutperform ➝ Overweight$54.00 ➝ $57.00
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight
2/26/2021Piper SandlerBoost TargetOverweight$50.00 ➝ $54.00
2/26/2021Leerink PartnersBoost TargetOutperform$40.00 ➝ $53.00
2/26/2021Raymond JamesBoost TargetIn-Line ➝ Strong-Buy$44.00 ➝ $56.00
12/15/2020Smith Barney CitigroupBoost Target$40.00 ➝ $49.00
12/8/2020Berenberg BankInitiated CoverageBuy$44.00
11/11/2020Cantor FitzgeraldReiterated RatingOverweight
11/11/2020Royal Bank of CanadaBoost TargetOutperform$34.00 ➝ $40.00
11/11/2020Raymond JamesBoost TargetPositive ➝ Strong-Buy$40.00 ➝ $44.00
8/18/2020GuggenheimBoost Target$33.00 ➝ $37.00
8/12/2020Truist FinancialBoost Target$36.00 ➝ $43.00
8/12/2020Stifel NicolausBoost TargetBuy$36.00 ➝ $37.00
7/14/2020CitigroupInitiated CoverageBuy$40.00
7/10/2020Leerink PartnersBoost TargetOutperform$32.00 ➝ $40.00
6/18/2020Stifel NicolausInitiated CoverageBuy$36.00
6/4/2020Cantor FitzgeraldReiterated RatingBuy$44.00
5/15/2020GuggenheimInitiated CoverageBuy$33.00
5/13/2020SunTrust BanksBoost TargetBuy$30.00 ➝ $36.00
5/13/2020Royal Bank of CanadaBoost TargetOutperform$30.00 ➝ $34.00
5/13/2020Raymond JamesLower TargetStrong-Buy$46.00 ➝ $40.00
5/13/2020Leerink PartnersBoost TargetOutperform$31.00 ➝ $32.00
4/22/2020SunTrust BanksLower TargetBuy$35.00 ➝ $30.00
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$30.00
4/20/2020Cantor FitzgeraldLower TargetPositive ➝ Overweight$47.00 ➝ $44.00
4/13/2020Leerink PartnersInitiated CoverageOutperform$31.00
3/26/2020SunTrust BanksLower TargetBuy$46.00 ➝ $35.00
12/19/2019Raymond JamesInitiated CoverageStrong-Buy$46.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/21/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/20/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2024
  • 6 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/19/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/18/2024
  • 12 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2024
  • 9 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/17/2024

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Health Catalyst logo
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
Read More

Today's Range

Now: $7.65
Low: $7.63
High: $8.59

50 Day Range

MA: $8.16
Low: $7.48
High: $8.86

52 Week Range

Now: $7.65
Low: $5.42
High: $11.41

Volume

735,511 shs

Average Volume

548,477 shs

Market Capitalization

$465.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Health Catalyst?

The following Wall Street research analysts have issued stock ratings on Health Catalyst in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, JPMorgan Chase & Co., KeyCorp, Piper Sandler, Royal Bank of Canada, Stephens, and Wells Fargo & Company.
View the latest analyst ratings for HCAT.

What is the current price target for Health Catalyst?

0 Wall Street analysts have set twelve-month price targets for Health Catalyst in the last year. Their average twelve-month price target is $11.71, suggesting a possible upside of 53.1%. Cantor Fitzgerald has the highest price target set, predicting HCAT will reach $16.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $9.00 for Health Catalyst in the next year.
View the latest price targets for HCAT.

What is the current consensus analyst rating for Health Catalyst?

Health Catalyst currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HCAT.

What other companies compete with Health Catalyst?

Other companies that are similar to Health Catalyst include Eventbrite, Cardlytics, Aurora Mobile, HealthStream and Model N. Learn More about companies similar to Health Catalyst.

How do I contact Health Catalyst's investor relations team?

Health Catalyst's physical mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company's listed phone number is (801) 708-6800 and its investor relations email address is [email protected]. The official website for Health Catalyst is www.healthcatalyst.com. Learn More about contacing Health Catalyst investor relations.